Heart scans to find and assess heart failure with preserved ejection fraction
Uses several heart scans to study early heart changes in people with HFpEF.
Plain-language title generated from the registry record
Registry title: Multimodality Imaging in the Screening, Diagnosis and Risk StratifictiON of HFpEF
Key facts
- Where
- Beijing, ChinaSee the site
Where in China
- Fuwai HospitalBeijing, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Chinese Academy of Medical Sciences, Fuwai Hospital
- Trial code
- NCT04603404
- Record updated
- 8 November 2022
- Original description
The incidence of Heart failure with preserved ejection fraction (HFpEF) in Heart failure patients increases rapidly. However, the current clinical awareness is insufficient, and the cardiac structural and functional injury are not well understood. It is difficult to recognize the subclinical changes of the cardiac in the early stage with conventional imaging techniques, and it is common to ignore the existence of the clinical alterations. This study aimed to investigate the cardiac features, early diagnosis and risk factors of HFpEF patients, based on the multi-modal (Magnetic resonance imaging- nuclear medicine imaging- echocardiography) imaging, combined with large data and artificial intelligence. This study will provide deep insights into the HFpEF derived from different causes.Read full original descriptionShow less
Multimodality Imaging (Cardiovascular Magnetic Resonance Imaging, Echocardiography, and Nuclear Medicine Imaging) in the Screening, Diagnosis and Risk Stratification of Heart Failure With Preserved Ejection Fraction (HFpEF).
The incidence of Heart failure with preserved ejection fraction (HFpEF) in Heart failure patients increases rapidly. However, the current clinical awareness is insufficient, and the cardiac structural and functional injury are not well understood. It is difficult to recognize the subclinical changes of the cardiac in the early stage with conventional imaging techniques, and it is common to ignore the existence of the clinical alterations. This study aimed to investigate the cardiac features, early diagnosis and risk factors of HFpEF patients, based on the multi-modal (Magnetic resonance imaging- nuclear medicine imaging- echocardiography) imaging, combined with large data and artificial intelligence. This study will provide deep insights into the HFpEF derived from different causes.
Inclusion: left ventricular ejection fraction (LVEF)≥50%；; N-terminal pro-b type natriuretic peptide (NT-proBNP)>220pg/ml or b type natriuretic peptide (BNP) >80 pg/ml; symptoms and syndromes of heart failure; At least one criteria of cardiac structure (left ventricular hypertrophy, or left atrial enlargement) and function abnormalities (based on tissue doppler, color doppler).
Exclusion: Infarction, myocardial fibrosis caused by ischemic cardiomyopathy and acute coronary syndrome ; Severe arrhythmia; Severe primary cardiac valvular disease; Restrictive pericardial disease; Special types of cardiomyopathy, including hypertrophic cardiomyopathy, restricted cardiomyopathy, etc; Refuse to participate in the study.